Clinical Study to Assess a New Barrier Film's Ability to Provide Skin Protection Against Incontinence & Allow Healing

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

45 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-10-31

Study Completion Date

2017-06-23

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to evaluate the safety and efficacy of the investigational product (3M™ Cavilon™ Advanced High Endurance Skin Protectant) for the treatment of incontinence associated dermatitis.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Demonstrate the Efficacy and Safety of Convatec ConvaFoam™ Silicone, ConvaFoam™ Border and ConvaFoam™ Non-adhesive Dressings to Protect Against Skin Breakdown

NCT05902182

Skin Breakdown

UNKNOWN NA

Medical Adhesive Repeat Application Study

NCT04869696

Healthy

COMPLETED

This Study Will Collect Clinical and Patient Reported Experience Data From Participants Requiring Urine Output Management Overnight in the Home Setting.

NCT06666426

Adult Nocturnal Enuresis Urinary Incontinence (UI)

COMPLETED NA

A Clinical Comparison of Two Marketed Skin Barriers on Healthy Volunteers

NCT01534039

Peristomal Skin Complication

COMPLETED PHASE4

Soliton Planar Acoustic Wave Device System for Dermal Tattoo Clearing Human Trial Protocol

NCT03125824

Tattooing

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The purpose of this study is to evaluated the product performance of a new skin protectant formulated to protect damaged and denuded skin even in the presence of exposure to the most potentially damaging body fluids, such as liquid stool and gastric fluid. The product is expected to intimately adhere to damaged and denuded skin and provide better protection from further damage than commonly used products such as moisture barrier pastes, thereby making it easier for nursing staff to cleanse the skin after incontinence episodes, thus saving time and also materials.

The denuded sites on buttocks/thighs will be scored for skin loss and degree of redness. Over the course of time, with the skin protected, it should re-epithelizes. The skin improvement will be scored and the change in baseline over time monitored.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Incontinence Associated Dermatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cavilon Advanced Skin Protectant

Product applicator contains liquid barrier applied on buttocks/thighs with it drying rapidly to durable barrier film. It's applied 3x/per week.

Group Type EXPERIMENTAL

Cavilon Advanced Skin Protectant

Intervention Type DEVICE

The liquid barrier film flows from the applicator and dries quickly on the skin. It is durable for 72-96 hours under conditions of incontinence.

ConvaTec Sensi-Care Protective Barrier

Marketed product applied following manufacturer's recommendation. The product is 15% zinc oxide with petrolatum.

Group Type ACTIVE_COMPARATOR

ConvaTec Sensi-Care Protective Barrier

Intervention Type DEVICE

Sensi-Care is commercial paste product applied to protect denuded and weeping skin from incontinence.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cavilon Advanced Skin Protectant

The liquid barrier film flows from the applicator and dries quickly on the skin. It is durable for 72-96 hours under conditions of incontinence.

Intervention Type DEVICE

ConvaTec Sensi-Care Protective Barrier

Sensi-Care is commercial paste product applied to protect denuded and weeping skin from incontinence.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Subjects may be enrolled into this study if the answers to all these questions are yes.

1. Is the subject a full-term newborn (36 weeks or greater gestational age) or older?
2. Is the subject in a facility providing nursing care 24 hours per day?
3. Does the subject have severe Category 2 Incontinence-Associated Dermatitis (IAD) -red with skin breakdown (i.e. skin erosion and denudation or denudation of skin alone)?
4. Is the subject willing to have photos taken of their skin exposed to incontinence and permit use of photographs in potential publication?
5. Is the subject willing to release rights to 3M for the use of the photos?
6. Is there a reasonable expectation that the subject will remain in a facility for at least 7 days following enrollment in the study?
7. Has the subject, or their legally authorized representative, signed an Institutional Review Board-approved informed consent/assent document and authorized the use and disclosure of protected health information?

Exclusion Criteria

* Subjects are excluded from participation in this study if any of the answers to these following questions is yes.

1. If female, is the subject pregnant or breast feeding or has she given birth within the 3 weeks preceding the screening visit?
2. Does the subject have a known allergy to acrylates or cyanoacrylates?
3. Does the subject have a Stage III, IV, unstageable, suspected deep tissue injury pressure ulcer in the area where the skin is affected by incontinence?
4. Does the subject have a preexisting skin disease on the areas affected by incontinence that may make skin assessments for this study difficult?
5. Does the skin area affected by incontinence require treatment with a concomitant medication or product?
6. Does the subject have an active genital herpes infection?
7. Has the subject received antifungal powders in the area affected with IAD within 24 hours prior to enrollment?
8. Has the subject received cyanoacrylate based skin protectant (such as Marathon) within 72 hours prior to enrollment?
9. Is the facility unwilling to discontinue use for this subject of Dimethicone-containing wipes on the area where the skin protectant product will be applied?
10. Is the facility unwilling to discontinue use for this subject of Chlorhexidine Gluconate wipes on the area where the skin protectant product will be applied?
11. Does the subject have any medical condition that in the opinion of the investigator should exclude him/her from participating in the study?
12. Has the subject been enrolled in any investigational study where product was applied to proposed study sites within 30 days of the screening visit?

Minimum Eligible Age

1 Hour

Eligible Sex

ALL

Accepts Healthy Volunteers

No